Skyhawk Therapeutics announced a newly formed RNA splicing-focused collaboration with Merck KGaA valued at up to $2 billion. The partnership targets neurological diseases, with Skyhawk deploying its SkySTAR RNA splicing platform to identify small molecule drug candidates against RNA targets selected by Merck. Skyhawk will manage discovery and preclinical development, while Merck holds options for clinical advancement and commercialization. This agreement adds to Skyhawk’s expanding roster of pharmaceutical partners and highlights RNA modulation's potential in tackling traditionally ‘undruggable’ targets in neurology and beyond.